

1 **MDA5 variants trade antiviral activity for protection from autoimmune**
2 **disease**

3 Chris Wallace^{1,2,*}, Rahul Singh^{1,3}, Yorgo Modis^{1,3,*}

4 ¹Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of
5 Cambridge School of Clinical Medicine, Cambridge, UK

6 ²MRC Biostatistics Unit, University of Cambridge, Cambridge, UK

7 ³Molecular Immunity Unit, Department of Medicine, University of Cambridge, MRC Laboratory of
8 Molecular Biology, Francis Crick Avenue, Cambridge, UK

9 *Correspondence: C.W., cew54@cam.ac.uk; Y.M., ymodis@mrc-lmb.cam.ac.uk

10

11 **Keywords:** Type 1 diabetes (T1D); inflammatory bowel disease (IBD); human genetic variants;
12 Genome-wide association studies (GWAS); fitness trade-off; autoimmune disease

13

14 **Running title:** MDA5 variants trade T1D protection for IBD risk

15 **Abstract**

16 Loss-of-function variants in MDA5, a key sensor of double-stranded RNA from viruses and
17 retroelements, have been associated with protection from type 1 diabetes (T1D) in genome-
18 wide association studies (GWAS). MDA5 loss-of-function variants have also been reported to
19 increase the risk of inflammatory bowel disease (IBD). Whether these associations are linked or
20 extend to other diseases remains unclear. Here, fine-mapping analysis of four large GWAS
21 datasets shows that T1D-protective loss-of-function MDA5 variants also protect against
22 psoriasis and hypothyroidism, while increasing the risk of IBD. The degree of autoimmune
23 protection and IBD risk were linearly proportional. The magnitudes of the odds ratios for
24 autoimmune protection and IBD risk were larger for rare MDA5 variants than for common
25 variants, which were differentially expressed in different geographic populations. Our analysis
26 suggests MDA5 genetic variants offer a direct fitness trade-off between viral clearance and
27 autoimmune tissue damage.

28

29 **Introduction**

30 Innate immune responses must be sensitive enough to detect infection yet specific enough to
31 avoid activation by cellular components. A key innate immune receptor for cytosolic double-
32 stranded RNA (dsRNA), a potent signature of viral infection, is MDA5¹⁻⁵. Recognition of dsRNA
33 by MDA5 induces a potent IFN- β response^{2,3}. The ATPase activity and dsRNA binding
34 cooperativity of MDA5 confer the necessary sensitivity and specificity of MDA5-dsRNA
35 recognition⁴⁻⁶. Mutations in the gene encoding MDA5, *IFIH1*, can perturb the balance between
36 sensitive and specific dsRNA recognition. *IFIH1* is a hotspot for natural variants with clinical
37 associations. Approximately 40 gain-of-function missense variants have been associated with
38 interferonopathies⁷⁻⁹. These variants promote formation of MDA5 signaling complexes, including
39 on endogenous dsRNAs, by either increasing the RNA binding affinity of MDA5 or inhibiting its

40 ATP-dependent proofreading activity^{5,9,10}. Loss-of-function MDA5 variants cause recurrent
41 infections¹¹, and have been reported to contribute to inflammatory bowel disease (IBD),
42 including ulcerative colitis and Crohn's disease^{12,13}. GWAS data have also associated loss-of-
43 function MDA5 variants with reduced risk of developing certain autoimmune diseases, most
44 notably T1D¹⁴⁻¹⁹. Specifically, variants E627* (rs35744605), R843H (rs3747517), I923V
45 (rs35667974), and T946A (rs1990760) have been identified as T1D-protective^{14-18,20,21}. The
46 E627* and I923V variants are rare, with allele frequencies of 1-2%, while R843H and T946A are
47 common. These common variants are differentially expressed in different geographic
48 populations. The T946A variant is present in 70-80% of Africans and Asians but only 30-50% of
49 Caucasians^{15-18,20}. Similarly, the R843H variant is found in 70% of Asians but only 30-40% of
50 Caucasians and Africans^{15-18,20}. Most human *IFIH1* reference sequences contain the alleles that
51 are most common in Asians (Ala946/His843). These coding variants inhibit the formation of
52 MDA5-dsRNA signaling complexes^{18,22} by reducing the RNA binding affinity of MDA5 or
53 hyperactivating its ATPase activity²³. Other loss-of-function variants are splice donor variants
54 that reduce splicing efficiency and hence mRNA levels¹⁹.

55 A robust clinical link has emerged between T1D onset and recent infection with RNA
56 viruses, in particular coxsackieviruses and other enteroviruses²⁴. T1D patients have more
57 frequent and persistent enterovirus infections, which precede the appearance of prediabetic
58 markers, including autoantibodies²⁵. MDA5 recognizes RNA from *Picornaviridae*, including
59 enteroviruses^{1,26}, which have evolved mechanisms to suppress IFN- β transcription^{27,28}. MDA5-
60 induced inflammation in the pancreas following rotavirus infection contributes to autoimmune
61 destruction of pancreatic β -cells²⁹. Therefore, a plausible hypothesis is that MDA5-dependent
62 inflammation following viral infection can trigger autoimmune β -cell killing.

63 Gastrointestinal viral infection has also been linked to IBD onset³⁰. Intestinal cells from
64 IBD patients harboring loss-of-function MDA5 variants had elevated viral loads and were
65 compromised in their ability to maintain epithelial barrier integrity upon further exposure to the
66 enteric virome¹³. Hence, the frequency and clinical phenotypes of MDA5 loss-of-function
67 variants in IBD patients suggest that MDA5 deficiency contributes to the induction of IBD^{12,13},
68 due in part to increased exposure and susceptibility to viral infection^{11,13}.

69 **Results and Discussion**

70 Loss-of-function MDA5 variants have been associated with recurrent infection¹¹, T1D
71 protection¹⁴⁻¹⁹, and IBD risk^{12,13}. However, whether these associations are linked, or whether
72 they apply to autoimmune disease more broadly, has not been explored. We addressed these
73 questions by utilizing larger, more recent GWAS studies to conduct a broader, more sensitive
74 survey of immune-mediated disease associations involving MDA5 variants. For our analysis, we
75 selected GWAS datasets to maximize the likelihood of accurate fine mapping – balancing the
76 need for large sample size, minimizing the use of imputed genotypes, and using ancestries that
77 best matched the reference panel used to derive linkage disequilibrium (LD) estimates³¹⁻³⁴ (see
78 **Methods**). By reviewing associations with a reported lead T1D-associated variant, I923V
79 (rs35667974)¹⁵ we identified psoriasis, hypothyroidism, Crohn's disease, and ulcerative colitis
80 as additional associated diseases. Fine-mapping analysis using GWAS summary data for these
81 five diseases identified four variants likely to be causally associated with a subset of the
82 diseases, with considerable overlap of variants between diseases (**Fig. 1, Table 1**). Two of
83 these variants were coding variants, I923V and T946A, and two were splice donor variants,
84 rs35337543 and rs35732034. All four variants were previously associated with T1D protection¹⁴⁻
85 ¹⁹.

86 Given the overlaps between diseases, and the small P values observed for fine-mapped
87 variants in one disease when considering another, we called associated variants by considering
88 marginal association at any of these variants or other known loss-of-function variants not in LD
89 with any of the index variants using a stringent Bonferroni correction. This identified
90 associations of a fifth variant, E627* (rs35744605), with psoriasis, and hypothyroidism (**Fig. 1**).
91 While T946A is common, the other variants are rare (allele frequency below 3%). Fine-mapping
92 analysis did not find evidence for causality for variants E627* and R843H (**Table 1**). However,
93 for E627* the lack of evidence of causality is likely due to its low allele frequency (0.7%), which
94 limits power in genetics studies. In contrast, association of R843H with T1D protection is likely
95 attributable to LD with the co-occurring causal T946A allele ($r^2 = 0.60$), as previously
96 reported^{15,16,18}. Supporting these conclusions, our accompanying biochemical and structural
97 study of T1D-protective MDA5 variants shows that the E627* variant lacks signaling activity due
98 to a loss of RNA binding affinity, whereas the R843H substitution had no effect on the structural,
99 biochemical or signaling activities of MDA5²³.

100 Comparing associations across diseases, we found that all five associated variants
101 offered protection against T1D, psoriasis and hypothyroidism, but increased the risk of
102 ulcerative colitis and Crohn's disease (**Fig. 2a**). Remarkably, a strict correlation was observed
103 between protection and risk (**Fig. 2b**). A statistical test of proportionality (see **Methods**)
104 concluded that changes in risk were linearly proportional across variants (**Fig. 2c**). Additionally,
105 the magnitudes of the odds ratios were larger for the rare variants than for the common variants.
106 Thus, the rarest variant, I923V, conferred the greatest degree of T1D protection and the
107 greatest risk of IBD, whereas the most common variant, T946A, was associated with the least
108 T1D protection and IBD risk (**Fig. 2a-b**). Notably, the T946A variant, while common in all
109 populations, is the major allele in Asian and African populations but the minor allele in
110 Caucasians.

111 Our GWAS meta-analysis uncovers a direct correlation between protection from
112 autoimmune-related diseases (T1D, psoriasis and hypothyroidism) and increased risk of IBD.
113 The implication is that calibration of MDA5-dependent antiviral signaling offers a fundamental
114 fitness trade-off. Loss-of-function MDA5 variants protect from autoimmune tissue damage,
115 including to pancreatic β -cells leading to T1D, but increase the risk of inflammatory tissue
116 damage from persistent infection, including by enteric viruses in intestinal epithelia leading to
117 IBD. This model predicts that gain-of-function MDA5 variants protect from chronic inflammation
118 and IBD by ensuring infections are cleared but do so at the cost of increasing the risk of T1D
119 and other autoimmune diseases.

120 **Methods**

121 **GWAS meta-analysis**

122 GWAS summary data for a reported lead T1D-associated variant, I923V (rs35667974) were
123 downloaded for the following diseases: T1D (16,000 T1D cases, 25,000 controls)³¹; IBD (5,956
124 Crohn's disease cases, 6,968 ulcerative colitis cases, 21,770 controls)³²; psoriasis (19,032
125 cases, 286,769 controls)³³; and hypothyroidism (20,563 cases, 399,910 controls)³⁴. Data were
126 downloaded from the GWAS catalog from the following repositories: ulcerative colitis,
127 [https://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST003001-](https://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST003001-GCST004000/GCST003045/harmonised/26192919-GCST003045-EFO_0000729.h.tsv.gz)
128 [GCST004000/GCST003045/harmonised/26192919-GCST003045-EFO_0000729.h.tsv.gz](https://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST003045/harmonised/26192919-GCST003045-EFO_0000729.h.tsv.gz)
129 (ImmunoChip); Crohn's disease,
130 [https://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST003001-](https://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST003001-GCST004000/GCST003044/harmonised/26192919-GCST003044-EFO_0000384.h.tsv.gz)
131 [GCST004000/GCST003044/harmonised/26192919-GCST003044-EFO_0000384.h.tsv.gz](https://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST003044/harmonised/26192919-GCST003044-EFO_0000384.h.tsv.gz)
132 (ImmunoChip); T1D,
133 [https://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST90013001-](https://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST90013001-GCST90014000/GCST90013445/GCST90013445_buildGRCh38.tsv)
134 [GCST90014000/GCST90013445/GCST90013445_buildGRCh38.tsv](https://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST90013445/GCST90013445_buildGRCh38.tsv) (ImmunoChip); Psoriasis:
135 http://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST005001-

136 [GCST006000/GCST005527/harmonised/23143594-GCST005527-EFO_0000676.h.tsv.gz](https://www.ebi.ac.uk/summary/136)
137 (Meta analysis); Hypothyroidism: [https://pan-ukb-us-east-](https://pan-ukb-us-east-1.s3.amazonaws.com/sumstats_flat_files/categorical-20002-both_sexes-1453.tsv.bgz)
138 [1.s3.amazonaws.com/sumstats_flat_files/categorical-20002-both_sexes-1453.tsv.bgz](https://pan-ukb-us-east-1.s3.amazonaws.com/sumstats_flat_files/categorical-20002-both_sexes-1453.tsv.bgz) (genome
139 wide SNP chip). These studies were selected to balance the need for large studies and those
140 most likely to give accurate results in fine mapping – i.e. those which minimized imputation and
141 most closely matched the ancestry of our reference LD panel.

142 Alleles were aligned to the UK Biobank as a common reference. Reference LD matrices
143 were estimated from 40,000 European subjects from UK Biobank. Fine mapping was performed
144 with a variant of the Sum of Single Effects (SuSiE)³⁵ model, as implemented in susieR³⁶.

145 rs72871627 was selected as a tag ($r^2 = 0.99$) of the splice donor variant rs35337543
146 because rs72871627 was available in all GWAS datasets whereas rs35337543 was only
147 available in the T1D GWAS dataset.

148 Tests of proportional effects between pairs of diseases were performed across all variants in
149 Table X using colocPropTest [<https://cran.r-project.org/package=colocPropTest>] which
150 implements the test of proportionality as previously described³⁷.

151 **Data Availability**

152 This study is a meta-analysis of previously published data. All code to reproduce this analysis is
153 available at Zenodo.org [<https://doi.org/10.5281/zenodo.12771481>].

154 **Competing Interests**

155 Y.M. is a consultant for Related Sciences LLC. The remaining authors declare no competing
156 interests.

157 **Author Contributions**

158 Conceptualization, C.E.W., R.S. and Y.M.; Methodology, C.E.W.; Formal Analysis, C.E.W. and
159 Y.M.; Funding Acquisition, Y.M.; Project Administration, Y.M.; Software, C.E.W.; Supervision,
160 Y.M.; Writing – Original Draft, Y.M.; Writing – Review & Editing, C.E.W., R.S. and Y.M.

161 **Acknowledgements**

162 We thank Louise Modis, Tetsuo Hasegawa, and the Modis group for useful discussions. This
163 work was supported by the Wellcome Trust [217191/Z/19/Z to Y.M.].

164


165 **References**

- 166 1. Kato H, *et al.* Differential roles of MDA5 and RIG-I helicases in the recognition of RNA
167 viruses. *Nature* **441**, 101-105 (2006).
- 168 2. Peisley A, *et al.* Cooperative assembly and dynamic disassembly of MDA5 filaments for
169 viral dsRNA recognition. *Proc Natl Acad Sci U S A* **108**, 21010-21015 (2011).
- 170 3. Berke IC, Modis Y. MDA5 cooperatively forms dimers and ATP-sensitive filaments upon
171 binding double-stranded RNA. *EMBO J* **31**, 1714-1726 (2012).
- 172 4. Yu Q, Qu K, Modis Y. Cryo-EM Structures of MDA5-dsRNA Filaments at Different Stages of
173 ATP Hydrolysis. *Mol Cell* **72**, 999-1012 e1016 (2018).
- 174 5. Yu Q, Herrero Del Valle A, Singh R, Modis Y. MDA5 disease variant M854K prevents ATP-
175 dependent structural discrimination of viral and cellular RNA. *Nat Commun* **12**, 6668 (2021).
- 176 6. Singh R, *et al.* Contrasting functions of ATP hydrolysis by MDA5 and LGP2 in viral RNA
177 sensing. *J Biol Chem* **300**, 105711 (2024).
- 178 7. Rodero MP, Crow YJ. Type I interferon-mediated monogenic autoinflammation: The type I
179 interferonopathies, a conceptual overview. *J Exp Med* **213**, 2527-2538 (2016).
- 180 8. Rutsch F, *et al.* A specific IFIH1 gain-of-function mutation causes Singleton-Merten
181 syndrome. *Am J Hum Genet* **96**, 275-282 (2015).

- 182 9. Rice GI, *et al.* Genetic and phenotypic spectrum associated with IFIH1 gain-of-function.
183 *Hum Mutat* **41**, 837-849 (2020).
- 184 10. Garau J, *et al.* Molecular Genetics and Interferon Signature in the Italian Aicardi Goutieres
185 Syndrome Cohort: Report of 12 New Cases and Literature Review. *J Clin Med* **8**, 750
186 (2019).
- 187 11. Lamborn IT, *et al.* Recurrent rhinovirus infections in a child with inherited MDA5 deficiency.
188 *J Exp Med* **214**, 1949-1972 (2017).
- 189 12. Cananzi M, *et al.* IFIH1 loss-of-function variants contribute to very early-onset inflammatory
190 bowel disease. *Hum Genet* **140**, 1299-1312 (2021).
- 191 13. Adiliaghdam F, *et al.* Human enteric viruses autonomously shape inflammatory bowel
192 disease phenotype through divergent innate immunomodulation. *Sci Immunol* **7**, eabn6660
193 (2022).
- 194 14. Smyth DJ, *et al.* A genome-wide association study of nonsynonymous SNPs identifies a
195 type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. *Nat Genet* **38**, 617-
196 619 (2006).
- 197 15. Nejentsev S, Walker N, Riches D, Egholm M, Todd JA. Rare variants of IFIH1, a gene
198 implicated in antiviral responses, protect against type 1 diabetes. *Science* **324**, 387-389
199 (2009).
- 200 16. Liu S, *et al.* IFIH1 polymorphisms are significantly associated with type 1 diabetes and
201 IFIH1 gene expression in peripheral blood mononuclear cells. *Hum Mol Genet* **18**, 358-365
202 (2009).
- 203 17. Vasseur E, *et al.* The selective footprints of viral pressures at the human RIG-I-like receptor
204 family. *Hum Mol Genet* **20**, 4462-4474 (2011).
- 205 18. Gorman JA, *et al.* The A946T variant of the RNA sensor IFIH1 mediates an interferon
206 program that limits viral infection but increases the risk for autoimmunity. *Nat Immunol* **18**,
207 744-752 (2017).


- 208 19. Downes K, *et al.* Reduced expression of IFIH1 is protective for type 1 diabetes. *PLoS One*
209 **5**, (2010).
- 210 20. de Azevedo Silva J, *et al.* Meta-analysis of STAT4 and IFIH1 polymorphisms in type 1
211 diabetes mellitus patients with autoimmune polyglandular syndrome type III. *Genet Mol Res*
212 **14**, 17730-17738 (2015).
- 213 21. Jermendy A, Szatmari I, Korner A, Szabo AJ, Toth-Heyn P, Hermann R. Association
214 between interferon-induced helicase (IFIH1) rs1990760 polymorphism and seasonal
215 variation in the onset of type 1 diabetes mellitus. *Pediatr Diabetes* **19**, 300-304 (2018).
- 216 22. Shigemoto T, Kageyama M, Hirai R, Zheng J, Yoneyama M, Fujita T. Identification of loss
217 of function mutations in human genes encoding RIG-I and MDA5: implications for
218 resistance to type I diabetes. *J Biol Chem* **284**, 13348-13354 (2009).
- 219 23. Singh R, *et al.* Molecular basis of pathogenesis and protection from type 1 diabetes by loss
220 of function MDA5 variants. *bioRxiv*, (2024).
- 221 24. Yeung WC, Rawlinson WD, Craig ME. Enterovirus infection and type 1 diabetes mellitus:
222 systematic review and meta-analysis of observational molecular studies. *BMJ* **342**, d35
223 (2011).
- 224 25. Hyoty H, Taylor KW. The role of viruses in human diabetes. *Diabetologia* **45**, 1353-1361
225 (2002).
- 226 26. Wang JP, Cerny A, Asher DR, Kurt-Jones EA, Bronson RT, Finberg RW. MDA5 and MAVS
227 mediate type I interferon responses to coxsackie B virus. *J Virol* **84**, 254-260 (2010).
- 228 27. Visser LJ, *et al.* Essential Role of Enterovirus 2A Protease in Counteracting Stress Granule
229 Formation and the Induction of Type I Interferon. *J Virol* **93**, (2019).
- 230 28. Hato SV, *et al.* The mengovirus leader protein blocks interferon-alpha/beta gene
231 transcription and inhibits activation of interferon regulatory factor 3. *Cell Microbiol* **9**, 2921-
232 2930 (2007).

- 233 29. Dou Y, Yim HC, Kirkwood CD, Williams BR, Sadler AJ. The innate immune receptor MDA5
234 limits rotavirus infection but promotes cell death and pancreatic inflammation. *EMBO J* **36**,
235 2742-2757 (2017).
- 236 30. Axelrad JE, *et al.* Gastrointestinal Infection Increases Odds of Inflammatory Bowel Disease
237 in a Nationwide Case-Control Study. *Clin Gastroenterol Hepatol* **17**, 1311-1322 e1317
238 (2019).
- 239 31. Robertson CC, *et al.* Fine-mapping, trans-ancestral and genomic analyses identify causal
240 variants, cells, genes and drug targets for type 1 diabetes. *Nat Genet* **53**, 962-971 (2021).
- 241 32. Liu JZ, *et al.* Association analyses identify 38 susceptibility loci for inflammatory bowel
242 disease and highlight shared genetic risk across populations. *Nat Genet* **47**, 979-986
243 (2015).
- 244 33. Tsoi LC, *et al.* Large scale meta-analysis characterizes genetic architecture for common
245 psoriasis associated variants. *Nat Commun* **8**, 15382 (2017).
- 246 34. Karczewski KJ, *et al.* Pan-UK Biobank GWAS improves discovery, analysis of genetic
247 architecture, and resolution into ancestry-enriched effects. *bioRxiv*,
248 2024.2003.2013.24303864 (2024).
- 249 35. Wang G, Sarkar A, Carbonetto P, Stephens M. A simple new approach to variable selection
250 in regression, with application to genetic fine mapping. *J R Stat Soc Series B Stat Methodol*
251 **82**, 1273-1300 (2020).
- 252 36. Zou Y, Carbonetto P, Wang G, Stephens M. Fine-mapping from summary data with the
253 "Sum of Single Effects" model. *PLoS genetics* **18**, e1010299 (2022).
- 254 37. Wallace C. Statistical testing of shared genetic control for potentially related traits. *Genet*
255 *Epidemiol* **37**, 802-813 (2013).
- 256
- 257



258

259 **Fig. 1. Manhattan plots of fine-mapped variants for five diseases.** Colored circles indicate
 260 the fine mapping sets identified, and colored text labels the most likely causal SNP in each set,
 261 selected due its known function on MDA5. Known loss-of-function SNPs that were not in any
 262 fine mapping set are marked with "x" and a black label. Lower right, minor allele frequency
 263 (MAF) and function of fine-mapped SNPs.



264
 265 **Figure 2. GWAS meta-analysis of loss-of-function MDA5 variants. (a)** Effect sizes expressed in terms
 266 of the odd ratio for selected MDA5 loss-of-function variants. [‡]Because rs35337543 was only available in
 267 two GWAS datasets, rs72871627 ($r^2 = 0.973$) was used as a tag for rs35337543. EAF, effect allele
 268 frequency. Error bars, SEM. ns, $P > 0.05$; *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$; ****, $P < 5 \times 10^{-8}$
 269 (genome-wide significance), where P is the Bonferroni-adjusted P value from marginal association
 270 analysis. CV, likely causal variant present in a credible set in fine-mapping analysis. R843H was included
 271 in fine-mapping analysis but excluded from marginal association analysis. See **Table 1.** (b) Odds ratio
 272 plot for variants and diseases in (a). (c) Estimated effect sizes in hypothyroidism compared to the other
 273 diseases. Hypothyroidism was selected because it was the largest dataset for which all SNPs were
 274 available. Dashed lines, identity and negative identity lines.
 275

276 **Table 1. Marginal association and fine-mapping analysis results.**

Variant	SNP	Location	Allele	EAF	Disease	lnOR ± std. err.	OR	P	P _{Bonferroni}	Causal [‡]
I923V	rs35667974	2:162268127	T>C	0.022	T1D	-0.493 ± 0.062	0.611	1.21×10 ⁻¹⁵	2.91×10 ⁻¹⁴	T
					Psoriasis	-0.440 ± 0.129	0.644	6.68×10 ⁻⁴	0.0160	F
					Hypothy.	-0.254 ± 0.038	0.776	2.98×10 ⁻¹¹	7.16×10 ⁻¹⁰	T
					Crohn's	0.121 ± 0.046	1.129	8.08×10 ⁻³	0.1938	F
					UC	0.276 ± 0.046	1.318	1.94×10 ⁻⁹	4.64×10 ⁻⁸	T
Splice1	rs35732034	2:162268086	C>T	0.010	Psoriasis	-0.693 ± 0.253	0.500	6.25×10 ⁻³	0.1500	F
					T1D	-0.464 ± 0.083	0.629	2.29×10 ⁻⁸	5.50×10 ⁻⁷	T
					Hypothy.	-0.230 ± 0.056	0.794	4.47×10 ⁻⁵	1.07×10 ⁻³	F
					UC	0.180 ± 0.067	1.197	7.70×10 ⁻³	0.1848	F
					Crohn's	0.226 ± 0.064	1.253	4.15×10 ⁻⁴	9.96×10 ⁻³	F
Splice2*	rs72871627	2:162280432	A>G	0.015	Psoriasis	-0.541 ± 0.200	0.582	6.81×10 ⁻³	0.1634	F
					T1D	-0.458 ± 0.073	0.633	4.19×10 ⁻¹⁰	1.00×10 ⁻⁸	T
					Hypothy.	-0.253 ± 0.046	0.777	2.94×10 ⁻⁸	7.05×10 ⁻⁷	T
					Crohn's	0.072 ± 0.056	1.074	0.1990	1	F
					UC	0.308 ± 0.054	1.360	1.19×10 ⁻⁸	2.85×10 ⁻⁷	T
Splice2	rs35337543	2:162279995	C>G	0.015	T1D	-0.458 ± 0.073	0.633	4.19×10 ⁻¹⁰	ND	T
					Hypothy.	-0.236 ± 0.045	0.790	1.51×10 ⁻⁷	ND	T
E627*	rs35744605	2:162277580	C>A	0.007	Hypothy.	-0.273 ± 0.068	0.761	5.63×10 ⁻⁵	1.35×10 ⁻³	F
					Psoriasis	-0.210 ± 0.372	0.810	0.5717	1	F
T946A	rs1990760	2:162267541	T>C	0.389	Psoriasis	-0.192 ± 0.034	0.825	1.95×10 ⁻⁸	4.68×10 ⁻⁷	T
					T1D	-0.132 ± 0.013	0.876	5.57×10 ⁻²⁴	1.34×10 ⁻²²	T
					Hypothy.	-0.080 ± 0.011	0.923	5.61×10 ⁻¹³	1.35×10 ⁻¹¹	T
					Crohn's	0.053 ± 0.013	1.055	3.36×10 ⁻⁵	8.07×10 ⁻⁴	F
					UC	0.086 ± 0.013	1.089	1.78×10 ⁻¹⁰	4.27×10 ⁻⁹	T
R843H	rs3747517	2:162272314	C>T	0.276	T1D	-0.111 ± 0.014	0.895	2.94×10 ⁻¹⁵	ND	F
					Psoriasis	-0.103 ± 0.035	0.903	3.72×10 ⁻³	ND	F
					Hypothy.	-0.068 ± 0.012	0.934	1.85×10 ⁻⁸	ND	F
					Crohn's	0.030 ± 0.014	1.031	0.0301	ND	F
					UC	0.051 ± 0.014	1.053	3.85×10 ⁻⁴	ND	F
N160D	rs74162075	2-162310909	T>C	0.001	Psoriasis	-2.057 ± 0.811	0.128	0.0111	0.2674	F
					Hypothy.	-0.270 ± 0.133	0.763	0.0427	1	F

277 EAF, effect allele frequency; OR, odds ratio.

278 *rs72871627 was used as a tag of rs35337543 because the latter was not available in all GWAS
279 datasets.

280 ‡Causality was inferred from presence of the SNP in a credible set in fine mapping analysis.

281 Dashed lines indicate that the SNPs above and below the line are in LD with each other.